

Dimitrios C Ziogas

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/8435682/publications.pdf>

Version: 2024-02-01

87
papers

2,123
citations

279798

23
h-index

276875

41
g-index

87
all docs

87
docs citations

87
times ranked

3408
citing authors

#	ARTICLE	IF	CITATIONS
1	Latest evidence on immune checkpoint inhibitors in metastatic colorectal cancer: A 2022 update. <i>Critical Reviews in Oncology/Hematology</i> , 2022, 173, 103663.	4.4	27
2	Efficacy and safety of sequencing with vemurafenib (V) plus cobimetinib (C) followed by atezolizumab (Atezo) in patients (pts) with advanced BRAF ^{V600} -positive melanoma: Interim analysis of the ImmunoCobiVem study.. <i>Journal of Clinical Oncology</i> , 2022, 40, 9548-9548.	1.6	6
3	EMRseq: Registry-based outcome analysis on 1,000 patients with BRAF V600-mutated metastatic melanoma in Europe treated with either immune checkpoint or BRAF-/MEK inhibition.. <i>Journal of Clinical Oncology</i> , 2022, 40, 9540-9540.	1.6	5
4	Beyond Immunotherapy: Seizing the Momentum of Oncolytic Viruses in the Ideal Platform of Skin Cancers. <i>Cancers</i> , 2022, 14, 2873.	3.7	1
5	A clinical audit of pneumococcal vaccination among patients with autoimmune rheumatic diseases living in Greece: The power of awareness. <i>Vaccine</i> , 2021, 39, 1593-1597.	3.8	5
6	Extending the conversation over the immune-related hepatotoxicity: author response to Dr. Gauci et al., 2021, 9, e002391.		3
7	Combining BRAF/MEK Inhibitors with Immunotherapy in the Treatment of Metastatic Melanoma. <i>American Journal of Clinical Dermatology</i> , 2021, 22, 301-314.	6.7	18
8	Granulomatous colitis in a patient with metastatic melanoma under immunotherapy: a case report and literature review. <i>BMC Gastroenterology</i> , 2021, 21, 227.	2.0	7
9	Atezolizumab plus vemurafenib and cobimetinib for the treatment of BRAF V600-mutant advanced melanoma: from an hypothetic triplet to an approved regimen. <i>Expert Review of Precision Medicine and Drug Development</i> , 2021, 6, 349-360.	0.7	0
10	Antibody-Drug Conjugates: Functional Principles and Applications in Oncology and Beyond. <i>Vaccines</i> , 2021, 9, 1111.	4.4	22
11	Neuromuscular Complications of Targeted Anticancer Agents: Can Tyrosine Kinase Inhibitors Induce Myasthenia Gravis? Getting Answers From a Case Report up to a Systematic Review. <i>Frontiers in Oncology</i> , 2021, 11, 727010.	2.8	2
12	The diagnosis and management of sarcoid-like reactions in patients with melanoma treated with BRAF and MEK inhibitors. A case series and review of the literature. <i>Therapeutic Advances in Medical Oncology</i> , 2021, 13, 17588359211047349.	3.2	0
13	The diagnosis and management of sarcoid-like reactions in patients with melanoma treated with BRAF and MEK inhibitors. A case series and review of the literature. <i>Therapeutic Advances in Medical Oncology</i> , 2021, 13, 175883592110473.	3.2	9
14	Identifying the optimum first-line therapy in BRAF-mutant metastatic melanoma. <i>Expert Review of Anticancer Therapy</i> , 2020, 20, 53-62.	2.4	6
15	Reconsidering the management of patients with cancer with viral hepatitis in the era of immunotherapy. , 2020, 8, e000943.		23
16	Clinical considerations about the coexistence of melanoma and chronic lymphocytic leukemia in the era of targeted therapies, triggered by rare clinical scenarios. A case series and review of the literature. <i>Therapeutic Advances in Medical Oncology</i> , 2020, 12, 175883592096236.	3.2	1
17	An overview of antibody-drug conjugates in oncological practice. <i>Therapeutic Advances in Medical Oncology</i> , 2020, 12, 175883592096299.	3.2	15
18	Encephalitis in a Patient With Melanoma Treated With Immune Checkpoint Inhibitors: Case Presentation and Review of the Literature. <i>Journal of Immunotherapy</i> , 2020, 43, 224-229.	2.4	5

#	ARTICLE	IF	CITATIONS
19	When steroids are not enough in immune-related hepatitis: current clinical challenges discussed on the basis of a case report. , 2020, 8, e001322.		26
20	Prognosis and Management of <i>BRAF</i> V600E-Mutated Pregnancy-Associated Melanoma. <i>Oncologist</i> , 2020, 25, e1209-e1220.	3.7	7
21	Early Relapse After Autologous Transplant Is Associated With Very Poor Survival and Identifies an Ultra-High-Risk Group of Patients With Myeloma. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2020, 20, 445-452.	0.4	23
22	Immunotherapy for pancreatic cancer: A 2020 update. <i>Cancer Treatment Reviews</i> , 2020, 86, 102016.	7.7	276
23	Clinical characteristics and outcomes of oligosecretory and non-secretory multiple myeloma. <i>Annals of Hematology</i> , 2020, 99, 1251-1255.	1.8	17
24	Omitting chemotherapy in more patients with early breast cancer in the post-TAILORx era.. <i>Journal of Clinical Oncology</i> , 2020, 38, e12534-e12534.	1.6	1
25	Reactivation of tuberculosis in cancer patients following administration of immune checkpoint inhibitors: current evidence and clinical practice recommendations. , 2019, 7, 239.		81
26	Primary Treatment of Light Chain (AL) Amyloidosis with Bortezomib, Lenalidomide and Dexamethasone (VRD). <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2019, 19, S331-S332.	0.4	0
27	A new genetic variant of hereditary apolipoprotein A-I amyloidosis: a case-report followed by discussion of diagnostic challenges and therapeutic options. <i>BMC Medical Genetics</i> , 2019, 20, 23.	2.1	8
28	Pulmonary function abnormalities are common in patients with multiple myeloma and are independently associated with worse outcome. <i>Annals of Hematology</i> , 2019, 98, 1427-1434.	1.8	9
29	Bone marrow biopsy in low-risk monoclonal gammopathy of undetermined significance reveals a novel smoldering multiple myeloma risk group. <i>American Journal of Hematology</i> , 2019, 94, E146-E149.	4.1	11
30	Impact of Minimal Residual Disease Detection by Next-Generation Flow Cytometry in Multiple Myeloma Patients with Sustained Complete Remission after Frontline Therapy. <i>HemaSphere</i> , 2019, 3, e300.	2.7	20
31	Impact of last lenalidomide dose, duration, and IMiD-free interval in patients with myeloma treated with pomalidomide/dexamethasone. <i>Blood Advances</i> , 2019, 3, 4095-4103.	5.2	17
32	Primary treatment of light-chain amyloidosis with bortezomib, lenalidomide, and dexamethasone. <i>Blood Advances</i> , 2019, 3, 3002-3009.	5.2	37
33	Consolidation therapy with the combination of bortezomib and lenalidomide (VR) without dexamethasone in multiple myeloma patients after transplant: Effects on survival and bone outcomes in the absence of bisphosphonates. <i>American Journal of Hematology</i> , 2019, 94, 400-407.	4.1	21
34	Vulnerability variables among octogenerian myeloma patients: a single-center analysis of 110 patients. <i>Leukemia and Lymphoma</i> , 2019, 60, 619-628.	1.3	9
35	Combination of conventional culture, vial culture, and broad-range PCR of sonication fluid for the diagnosis of prosthetic joint infection. <i>Diagnostic Microbiology and Infectious Disease</i> , 2018, 92, 13-18.	1.8	20
36	POEMS Syndrome. <i>Hematologic Malignancies</i> , 2018, , 177-189.	0.2	1

#	ARTICLE	IF	CITATIONS
37	Growth differentiation factor-15 is a new biomarker for survival and renal outcomes in light chain amyloidosis. <i>Blood</i> , 2018, 131, 1568-1575.	1.4	44
38	The addition of IMiDs for patients with daratumumab-refractory multiple myeloma can overcome refractoriness to both agents. <i>Blood</i> , 2018, 131, 464-467.	1.4	54
39	Coexistence of leishmaniasis and multiple myeloma in the era of monoclonal antibody (anti-CD38 or Tj ETQq1 1 0.784314 rgBT /Ove 2018, 59, 983-987.	1.3	4
40	Efficacy of lenalidomide as salvage therapy for patients with AL amyloidosis. <i>Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis</i> , 2018, 25, 234-241.	3.0	24
41	Management of uterine sarcomas and prognostic indicators: real world data from a single-institution. <i>BMC Cancer</i> , 2018, 18, 1247.	2.6	29
42	Prognostic factors for multiple myeloma in the era of novel therapies. <i>Expert Review of Hematology</i> , 2018, 11, 863-879.	2.2	28
43	Evaluation of minimal residual disease using next-generation flow cytometry in patients with AL amyloidosis. <i>Blood Cancer Journal</i> , 2018, 8, 46.	6.2	39
44	Detection of MYD88 and CXCR4 mutations in cell-free DNA of patients with IgM monoclonal gammopathies. <i>Leukemia</i> , 2018, 32, 2617-2625.	7.2	40
45	Carfilzomib-Associated Renal Toxicity Is Common and Unpredictable: An Analysis of 114 Patients. <i>Blood</i> , 2018, 132, 1966-1966.	1.4	3
46	Treating ALK-positive non-small cell lung cancer. <i>Annals of Translational Medicine</i> , 2018, 6, 141-141.	1.7	23
47	Breakthroughs in the treatment of advanced squamous-cell NSCLC: not the neglected sibling anymore?. <i>Annals of Translational Medicine</i> , 2018, 6, 143-143.	1.7	13
48	Carfilzomib Induces Acute Endothelial Dysfunction Which Correlates with the Occurrence of Cardiovascular Events. <i>Blood</i> , 2018, 132, 3247-3247.	1.4	0
49	Consolidation with a Short Course of Daratumumab Improves Complete Response Rates in Patients with AL Amyloidosis or Lcdd. <i>Blood</i> , 2018, 132, 3246-3246.	1.4	0
50	Functional Cure, Defined As PFS of More Than 7 Years, Is Achieved in 9% of Myeloma Patients in the Era of Conventional Chemotherapy and of First-Generation Novel Anti-Myeloma Agents; A Single-Center Experience over 20-Year Period. <i>Blood</i> , 2018, 132, 1968-1968.	1.4	1
51	When to recommend a second autograft in patients with relapsed myeloma?. <i>Leukemia and Lymphoma</i> , 2017, 58, 781-787.	1.3	4
52	Outcomes of newly diagnosed myeloma patients requiring dialysis: renal recovery, importance of rapid response and survival benefit. <i>Blood Cancer Journal</i> , 2017, 7, e571-e571.	6.2	33
53	Addition of cyclophosphamide and higher doses of dexamethasone do not improve outcomes of patients with AL amyloidosis treated with bortezomib. <i>Blood Cancer Journal</i> , 2017, 7, e570-e570.	6.2	31
54	Renal outcomes in patients with AL amyloidosis: Prognostic factors, renal response and the impact of therapy. <i>American Journal of Hematology</i> , 2017, 92, 632-639.	4.1	48

#	ARTICLE	IF	CITATIONS
55	Evaluation of the Revised International Staging System in an independent cohort of unselected patients with multiple myeloma. <i>Haematologica</i> , 2017, 102, 593-599.	3.5	72
56	Hematologic and renal improvement of monoclonal immunoglobulin deposition disease after treatment with bortezomib-based regimens. <i>Leukemia and Lymphoma</i> , 2017, 58, 1832-1839.	1.3	24
57	Gefitinib: an "orphan" drug for non-small cell lung cancer. <i>Expert Opinion on Orphan Drugs</i> , 2017, 5, 899-906.	0.8	2
58	Low circulating mannan-binding lectin levels correlate with increased frequency and severity of febrile episodes in myeloma patients who undergo ASCT and do not receive antibiotic prophylaxis. <i>Bone Marrow Transplantation</i> , 2017, 52, 1537-1542.	2.4	2
59	Circulating autoantibodies to endogenous erythropoietin are associated with chronic hepatitis C virus infection-related anemia. <i>Hepatobiliary and Pancreatic Diseases International</i> , 2017, 16, 289-295.	1.3	2
60	Outcomes of Consecutive Patients With Newly Diagnosed Myeloma Requiring Dialysis: Dialysis Independence is Associated with Rapid Myeloma Response and Predicts for Longer Survival. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2017, 17, e62-e63.	0.4	0
61	Efficacy and safety of sorafenib in patients with advanced hepatocellular carcinoma: age is not a problem. <i>European Journal of Gastroenterology and Hepatology</i> , 2017, 29, 48-55.	1.6	18
62	An overview of the role of carfilzomib in the treatment of multiple myeloma. <i>Expert Opinion on Pharmacotherapy</i> , 2017, 18, 1883-1897.	1.8	23
63	Prior Lenalidomide Resistance and the Impact of IMiD-free Interval in Patients Treated with Pomalidomide and Dexamethasone. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2017, 17, e115-e116.	0.4	0
64	Cardiac and renal complications of carfilzomib in patients with multiple myeloma. <i>Blood Advances</i> , 2017, 1, 449-454.	5.2	89
65	Bortezomib-based triplets are associated with a high probability of dialysis independence and rapid renal recovery in newly diagnosed myeloma patients with severe renal failure or those requiring dialysis. <i>American Journal of Hematology</i> , 2016, 91, 499-502.	4.1	73
66	Carfilzomib for treating myeloma. <i>Expert Opinion on Orphan Drugs</i> , 2016, 4, 989-999.	0.8	2
67	Increased circulating VCAM-1 correlates with advanced disease and poor survival in patients with multiple myeloma: reduction by post-bortezomib and lenalidomide treatment. <i>Blood Cancer Journal</i> , 2016, 6, e428-e428.	6.2	19
68	Predicting the Outcome of Sjogren's Syndrome-Associated Non-Hodgkin's Lymphoma Patients. <i>PLoS ONE</i> , 2015, 10, e0116189.	2.5	77
69	Asymptomatic Bacteriuria in Women With Autoimmune Rheumatic Disease: Prevalence, Risk Factors, and Clinical Significance. <i>Clinical Infectious Diseases</i> , 2015, 60, 868-874.	5.8	9
70	Inflammation-induced functional connectivity of melanin-concentrating hormone and IL-10. <i>Peptides</i> , 2014, 55, 58-64.	2.4	13
71	Anti-melanin-concentrating hormone treatment attenuates chronic experimental colitis and fibrosis. <i>American Journal of Physiology - Renal Physiology</i> , 2013, 304, G876-G884.	3.4	9
72	Increased Susceptibility of Melanin-Concentrating Hormone-Deficient Mice to Infection with <i>Salmonella enterica</i> Serovar Typhimurium. <i>Infection and Immunity</i> , 2013, 81, 166-172.	2.2	9

#	ARTICLE	IF	CITATIONS
73	Intestinal Upregulation of Melanin-Concentrating Hormone in TNBS-Induced Enterocolitis in Adult Zebrafish. PLoS ONE, 2013, 8, e83194.	2.5	33
74	FDG-PET for detecting local tumor recurrence of ablated liver metastases: a diagnostic meta-analysis. Biomarkers, 2012, 17, 532-538.	1.9	13
75	Oxidative stress and inflammatory markers in the exhaled breath condensate of children with OSA. Sleep and Breathing, 2012, 16, 703-708.	1.7	48
76	Variants of the MTHFR gene and susceptibility to acute lymphoblastic leukemia in children: A synthesis of genetic association studies. Cancer Epidemiology, 2012, 36, 169-176.	1.9	20
77	The reporting quality of studies investigating the diagnostic accuracy of anti-CCP antibody in rheumatoid arthritis and its impact on diagnostic estimates. BMC Musculoskeletal Disorders, 2012, 13, 113.	1.9	13
78	Reduced Intestinal Tumorigenesis in APCmin Mice Lacking Melanin-Concentrating Hormone. PLoS ONE, 2012, 7, e41914.	2.5	8
79	Catechol-O-Methyltransferase val158met Polymorphism Predicts Placebo Effect in Irritable Bowel Syndrome. PLoS ONE, 2012, 7, e48135.	2.5	163
80	A Network Meta-analysis of Randomized Controlled Trials of Induction Treatments in Acute Myeloid Leukemia in the Elderly. Clinical Therapeutics, 2011, 33, 254-279.	2.5	27
81	Bone mineral density and genetic markers involved in three connected pathways (focal adhesion, actin) Tj ETQq1 1 0.784314 rgBT /Opa 698-708.	1.9	8
82	Meta-analysis: the effects of placebo treatment on gastroesophageal reflux disease. Alimentary Pharmacology and Therapeutics, 2010, 32, 29-42.	3.7	52
83	Serum correlates of the placebo effect in irritable bowel syndrome. Neurogastroenterology and Motility, 2010, 22, 285-e81.	3.0	32
84	You deserve what you eat: lessons learned from the study of the melanin-concentrating hormone (MCH)-deficient mice. Gut, 2010, 59, 1625-1634.	12.1	14
85	Field Synopsis and Synthesis of Genetic Association Studies in Osteoarthritis: The CUMAGAS-OSTEO Information System. American Journal of Epidemiology, 2010, 171, 851-858.	3.4	14
86	Analysis of the Quality of Reporting of Randomized Controlled Trials in Acute and Chronic Myeloid Leukemia, and Myelodysplastic Syndromes as Governed by the CONSORT Statement. Annals of Epidemiology, 2009, 19, 494-500.	1.9	42
87	MTHFR gene polymorphisms and response to chemotherapy in colorectal cancer: a meta-analysis. Pharmacogenomics, 2009, 10, 1285-1294.	1.3	36